Trial purpose
Cancer treatment
Tumor type
Lung cancer
Age
18+
Trial acronym
SKYSCRAPER-15
Clinical summary
Summary
Eligible participants will be randomly assigned to one of two treatment arms:
In the Experimental Arm, participants will receive atezolizumab and tiragolumab, which will both be administered intravenously (IV).
In the Placebo Comparator Arm, participants will receive atezolizumab and placebo via IV.
Conditions
This trial is treating people with non-small cell lung cancer who have had prior surgery and chemotherapy
Eligibility
Inclusion
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology
- Participants must have had complete resection of NSCLC
- Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy
- Participants must have recovered adequately from surgery and from adjuvant chemotherapy
- Tumor cell PD-L1 expression at >/= 1%
- Adequate hematologic and end-organ function.
Exclusion
- Any history of prior NSCLC within the last 5 years
- Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy
- NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene
Inclusion
- You have had a certain type of treatment or surgical procedure.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Hoffmann-La Roche
Scientific Title
A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information